S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
NASDAQ:TXMD

TherapeuticsMD - TXMD Stock Forecast, Price & News

$5.20
-0.05 (-0.95%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$5.15
$5.40
50-Day Range
$4.23
$7.09
52-Week Range
$1.99
$23.00
Volume
34,511 shs
Average Volume
54,653 shs
Market Capitalization
$48.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$125.00

TherapeuticsMD MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
2,303.8% Upside
$125.00 Price Target
Short Interest
Healthy
3.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$204,124 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From $2.47 to ($0.79) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.75 out of 5 stars

Medical Sector

781st out of 1,028 stocks

Pharmaceutical Preparations Industry

384th out of 501 stocks

TXMD stock logo

About TherapeuticsMD (NASDAQ:TXMD) Stock

TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Receive TXMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter.

TXMD Stock News Headlines

TheraputicsMD sells products rights for $153 million
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
“Future Fuel” will unleash $11 trillion wave of wealth
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
TherapeuticsMD Announces $7 Million Private Placement
TherapeuticsMD, Inc. (NASDAQ: TXMD)
See More Headlines
Receive TXMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter.

TXMD Company Calendar

Last Earnings
11/14/2022
Today
2/04/2023
Next Earnings (Estimated)
3/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TXMD
Previous Symbol
NYSEMKT:TXMD
Employees
416
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$125.00
High Stock Price Forecast
$125.00
Low Stock Price Forecast
$125.00
Forecasted Upside/Downside
+2,303.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$-172,410,000.00
Pretax Margin
-9.57%

Debt

Sales & Book Value

Annual Sales
$86.95 million
Book Value
($11.05) per share

Miscellaneous

Free Float
8,596,000
Market Cap
$48.98 million
Optionable
Optionable
Beta
1.22

Key Executives

  • Marlan WalkerMarlan Walker
    Chief Executive Officer
  • Hugh O'Dowd
    President & Director
  • Michael Donegan
    Chief Financial & Accounting Officer
  • Daniella Silva
    Chief Compliance Officer
  • Douglas Mike Steelman
    Vice President-Market Access













TXMD Stock - Frequently Asked Questions

Should I buy or sell TherapeuticsMD stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TXMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares.
View TXMD analyst ratings
or view top-rated stocks.

What is TherapeuticsMD's stock price forecast for 2023?

2 Wall Street analysts have issued twelve-month price objectives for TherapeuticsMD's stock. Their TXMD share price forecasts range from $125.00 to $125.00. On average, they expect the company's share price to reach $125.00 in the next twelve months. This suggests a possible upside of 2,303.8% from the stock's current price.
View analysts price targets for TXMD
or view top-rated stocks among Wall Street analysts.

How have TXMD shares performed in 2023?

TherapeuticsMD's stock was trading at $5.59 on January 1st, 2023. Since then, TXMD shares have decreased by 7.0% and is now trading at $5.20.
View the best growth stocks for 2023 here
.

When is TherapeuticsMD's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our TXMD earnings forecast
.

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD, Inc. (NASDAQ:TXMD) issued its earnings results on Monday, November, 14th. The company reported ($3.13) EPS for the quarter, missing analysts' consensus estimates of ($2.04) by $1.09. The business had revenue of $20.92 million for the quarter, compared to analysts' expectations of $30.20 million.

When did TherapeuticsMD's stock split?

TherapeuticsMD shares reverse split before market open on Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU).

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by many different retail and institutional investors. Top institutional shareholders include Simplex Trading LLC (0.00%), XR Securities LLC (0.00%), XR Securities LLC (0.00%), Equitec Proprietary Markets LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian Bernick, Cooper C Collins, Edward Borkowski, Gail K Naughton, James Darecca, Marlan D Walker, Marlan D Walker, Michael C Donegan, Michael C Donegan, Paul Bisaro, Robert G Finizio, Rubric Capital Management Lp, Tommy G Thompson and Tommy G Thompson.
View institutional ownership trends
.

How do I buy shares of TherapeuticsMD?

Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $5.20.

How much money does TherapeuticsMD make?

TherapeuticsMD (NASDAQ:TXMD) has a market capitalization of $48.98 million and generates $86.95 million in revenue each year. The company earns $-172,410,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

How many employees does TherapeuticsMD have?

The company employs 416 workers across the globe.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The official website for the company is www.therapeuticsmd.com. The company can be reached via phone at (561) 961-1900, via email at shareholder@broadridge.com, or via fax at 561-431-3389.

This page (NASDAQ:TXMD) was last updated on 2/5/2023 by MarketBeat.com Staff